Literature DB >> 11278257

FP prostanoid receptor activation of a T-cell factor/beta -catenin signaling pathway.

H Fujino1, J W Regan.   

Abstract

FP prostanoid receptors are G-protein-coupled receptors (GPCR) that consist of two known isoforms, FP(A) and FP(B). These isoforms, which are generated by alternative mRNA splicing, are identical except for their carboxyl-terminal domains. Previously we have shown that stimulation of both isoforms with prostaglandin F(2alpha) (PGF(2alpha)) activates the small G-protein Rho, leading to morphological changes consisting of cell rounding and the formation of cell aggregates. Following the removal of PGF(2alpha), however, FP(A)-expressing cells show rapid reversal of cell rounding, whereas FP(B)-expressing cells do not. We now show that acute treatment of FP(B)-expressing cells with PGF(2alpha) leads to a subcellular reorganization of beta-catenin, a decrease in the phosphorylation of cytoplasmic beta-catenin, and persistent stimulation of Tcf/Lef-mediated transcriptional activation. This does not occur in FP(A)-expressing cells and may underlie the differences between these isoforms with respect to the reversal of cell rounding. The Tcf/beta-catenin signaling pathway is known to mediate the actions of Wnt acting through the heptahelical receptor, Frizzled, and has not been associated previously with GPCR activation. Our findings expand the signaling possibilities for GPCRs and suggest novel roles for FP receptors in normal tissue development and malignant transformation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11278257     DOI: 10.1074/jbc.C100039200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  beta-Arrestin1 modulates lymphoid enhancer factor transcriptional activity through interaction with phosphorylated dishevelled proteins.

Authors:  W Chen; L A Hu; M V Semenov; S Yanagawa; A Kikuchi; R J Lefkowitz; W E Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-11       Impact factor: 11.205

2.  Aberrant expression of a beta-catenin gain-of-function mutant induces hyperplastic transformation in the mouse cornea.

Authors:  Yujin Zhang; Mindy K Call; Lung-Kun Yeh; Hongshan Liu; Tyler Kochel; I-Jong Wang; Pao-Hsien Chu; Makoto M Taketo; James V Jester; Winston W-Y Kao; Chia-Yang Liu
Journal:  J Cell Sci       Date:  2010-03-23       Impact factor: 5.285

3.  WNT-3A-induced β-catenin signaling does not require signaling through heterotrimeric G proteins.

Authors:  Carl-Fredrik Bowin; Asuka Inoue; Gunnar Schulte
Journal:  J Biol Chem       Date:  2019-06-24       Impact factor: 5.157

Review 4.  Can we safely target the WNT pathway?

Authors:  Michael Kahn
Journal:  Nat Rev Drug Discov       Date:  2014-07       Impact factor: 84.694

5.  Role of the ERC motif in the proximal part of the second intracellular loop and the C-terminal domain of the human prostaglandin F2alpha receptor (hFP-R) in G-protein coupling control.

Authors:  Andrea Pathe-Neuschäfer-Rube; Frank Neuschäfer-Rube; Gerhard P Püschel
Journal:  Biochem J       Date:  2005-05-15       Impact factor: 3.857

6.  G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the {beta}-catenin pathway.

Authors:  Ming Yang; Wendy W Zhong; Neelam Srivastava; Anthony Slavin; Jianxin Yang; Timothy Hoey; Songzhu An
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-18       Impact factor: 11.205

7.  Protease-activated receptor-1 (PAR1) acts via a novel Galpha13-dishevelled axis to stabilize beta-catenin levels.

Authors:  Hagit Turm; Myriam Maoz; Vered Katz; Yong-Jun Yin; Steffan Offermanns; Rachel Bar-Shavit
Journal:  J Biol Chem       Date:  2010-03-11       Impact factor: 5.157

Review 8.  Prostanoid receptor antagonists: development strategies and therapeutic applications.

Authors:  R L Jones; M A Giembycz; D F Woodward
Journal:  Br J Pharmacol       Date:  2009-07-15       Impact factor: 8.739

9.  Suppression of adipocyte differentiation by aldo-keto reductase 1B3 acting as prostaglandin F2alpha synthase.

Authors:  Ko Fujimori; Toshiyuki Ueno; Nanae Nagata; Kaori Kashiwagi; Kosuke Aritake; Fumio Amano; Yoshihiro Urade
Journal:  J Biol Chem       Date:  2010-01-21       Impact factor: 5.157

10.  Indomethacin decreases EP2 prostanoid receptor expression in colon cancer cells.

Authors:  Hiromichi Fujino; Xiao-bo Chen; John W Regan; Toshihiko Murayama
Journal:  Biochem Biophys Res Commun       Date:  2007-05-30       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.